Mega Lifesciences Public (MEGA) Fundamentals 2026 — P/E 16.1x, Revenue Analysis | SniperIQ
Mega Lifesciences Public (MEGA) is a TH-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ฿33.3B, trading at ฿38.25 on the SET. This SniperIQ fundamentals page covers Mega Lifesciences Public's valuation (P/E 16.1x, P/B 3.2x), profitability (net margin 14.4%), revenue (฿14.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Mega Lifesciences Public's market cap?
Mega Lifesciences Public (MEGA) has a market capitalization of approximately ฿33.3B, trading at ฿38.25 on the SET. Market cap moves with the live share price.
What is Mega Lifesciences Public's P/E ratio?
Mega Lifesciences Public's trailing twelve-month P/E ratio is 16.1x, with a price-to-book (P/B) of 3.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Mega Lifesciences Public?
Mega Lifesciences Public runs a net profit margin of 14.4%, a gross margin of 52.2%, and an operating margin of 21.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Mega Lifesciences Public generate?
Mega Lifesciences Public reported revenue of ฿14.1B for fiscal year 2025, with net income of ฿1.9B and earnings per share (EPS) of 2.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Mega Lifesciences Public pay a dividend?
Mega Lifesciences Public offers a trailing dividend yield of about 4.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Mega Lifesciences Public financially healthy?
Mega Lifesciences Public carries a debt-to-equity ratio of 0.06x and a current ratio of 2.29x, with a market beta of 0.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Mega Lifesciences Public a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Mega Lifesciences Public (MEGA) the key facts are: market cap ฿33.3B, P/E 16.1x, revenue ฿14.1B, 52-week range 27.75-40. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Mega Lifesciences Public's full fundamentals live
Get Mega Lifesciences Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.